You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

FOUGERA PHARMS Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for FOUGERA PHARMS

FOUGERA PHARMS has one hundred and five approved drugs.



Summary for FOUGERA PHARMS
US Patents:0
Tradenames:50
Ingredients:42
NDAs:105

Drugs and US Patents for FOUGERA PHARMS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fougera Pharms TRIAMCINOLONE ACETONIDE triamcinolone acetonide OINTMENT;TOPICAL 085691-003 Approved Prior to Jan 1, 1982 AT RX No No ⤷  Try for Free ⤷  Try for Free
Fougera Pharms FLUOCINONIDE fluocinonide OINTMENT;TOPICAL 074905-001 Aug 26, 1997 AB RX No No ⤷  Try for Free ⤷  Try for Free
Fougera Pharms Inc BETAMETHASONE VALERATE betamethasone valerate OINTMENT;TOPICAL 018865-001 Aug 31, 1983 AB RX Yes Yes ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for FOUGERA PHARMS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fougera Pharms SOLARAZE diclofenac sodium GEL;TOPICAL 021005-001 Oct 16, 2000 5,639,738 ⤷  Try for Free
Fougera Pharms CUTIVATE fluticasone propionate OINTMENT;TOPICAL 019957-001 Dec 14, 1990 4,335,121*PED ⤷  Try for Free
Fougera Pharms ACLOVATE alclometasone dipropionate OINTMENT;TOPICAL 018702-001 Dec 14, 1982 4,124,707 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for FOUGERA PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Gel 3% ➤ Subscribe 2009-12-16
➤ Subscribe Lotion 0.05% ➤ Subscribe 2008-07-28
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Fougera Pharms – Market Position, Strengths & Strategic Insights

In the dynamic world of pharmaceutical manufacturing, understanding the competitive landscape is crucial for success. This analysis focuses on Fougera Pharmaceuticals, a key player in the generic dermatology market. We'll explore Fougera's market position, strengths, and strategic insights to provide a comprehensive view of its role in the pharmaceutical industry.

Fougera Pharmaceuticals: An Overview

Fougera Pharmaceuticals has established itself as a leading manufacturer of generic topical medications. The company's focus on dermatology has positioned it as a significant player in this niche market.

Historical Background

Fougera's journey in the pharmaceutical industry dates back several decades. The company has built a reputation for producing high-quality, affordable generic alternatives to branded dermatological products.

Core Business Focus

Fougera specializes in developing and manufacturing a wide range of topical products, including creams, ointments, gels, lotions, and solutions[2]. This specialization has allowed the company to build deep expertise in formulation and production of dermatological medications.

Market Position and Acquisition by Sandoz

In 2012, Fougera Pharmaceuticals was acquired by Sandoz, a division of Novartis, in a strategic move that significantly impacted the generic dermatology market.

Acquisition Details

Sandoz completed the acquisition of Fougera Pharmaceuticals for USD 1.525 billion in cash[1]. This substantial investment underscores the value Sandoz saw in Fougera's market position and capabilities.

Market Leadership

The acquisition positioned Sandoz as the #1 global company in generic dermatology medicines[1]. This move created a combined entity with estimated annual global sales of nearly USD 620 million, primarily in the US market.

"The addition of Fougera's leading portfolio further strengthens Sandoz's differentiated products strategy and improves our ability to help patients and customers around the world by providing easier access to high-quality, affordable dermatological medicines," said Jeff George, Global Head of Sandoz[1].

Fougera's Strengths in the Pharmaceutical Landscape

Fougera's success in the generic dermatology market can be attributed to several key strengths.

Specialized Expertise

Fougera has developed strong dermatology development and manufacturing expertise, particularly in the area of topical products[1]. This specialized knowledge gives the company a competitive edge in formulating and producing complex dermatological medications.

Product Portfolio

As of 2012, Fougera offered 45 products and more than 200 SKUs in the US dermatology generics sector[6]. This extensive product range allows the company to meet diverse patient needs and maintain a strong market presence.

Innovation in Packaging

Fougera has demonstrated innovation in product packaging. For instance, its Imiquimod Cream 5% (Rx) is available in single-use foilpacs, a proprietary packaging innovation that enhances convenience and ensures proper dosing[7].

Strategic Insights: Fougera's Approach to Market Success

Fougera's strategic approach has been instrumental in its market success and attractiveness as an acquisition target.

Focus on First-to-Market Generics

Fougera has shown a commitment to developing cost-effective, first-to-market generic products. This strategy was exemplified by the launch of Imiquimod Cream 5% (Rx), the first generic approval from the FDA for this product[2].

Customer-Centric Approach

The company has maintained a strong focus on meeting customer needs. By providing a wide range of topical products, Fougera ensures that healthcare providers have access to affordable treatment options for their patients[7].

Regulatory Compliance and Quality

Fougera's success in receiving FDA approvals for its products demonstrates its commitment to regulatory compliance and product quality. The company has consistently received topical FDA approvals, more than any other topical generic company[7].

Impact on the Generic Dermatology Market

Fougera's strong market position and subsequent acquisition by Sandoz have had significant implications for the generic dermatology market.

Market Consolidation

The acquisition of Fougera by Sandoz represents a trend of consolidation in the generic pharmaceutical industry. This move has created a more competitive landscape, potentially leading to economies of scale and increased research and development capabilities.

Enhanced Global Reach

By joining forces with Sandoz, Fougera's products now have the potential for broader global distribution. Sandoz's presence in over 130 countries worldwide provides an opportunity to expand Fougera's existing sales base to new markets[6].

Challenges and Opportunities in the Pharmaceutical Landscape

While Fougera has demonstrated significant strengths, the pharmaceutical industry presents both challenges and opportunities.

Regulatory Hurdles

The pharmaceutical industry is heavily regulated, and companies must navigate complex approval processes. Fougera's success in obtaining FDA approvals suggests a strong capability in this area, but ongoing regulatory changes may present future challenges.

Market Competition

The generic dermatology market is competitive, with multiple players vying for market share. Fougera's specialized focus and broad product portfolio provide a competitive advantage, but the company must continue to innovate to maintain its market position.

Opportunities for Growth

The global dermatology market continues to grow, driven by factors such as increasing skin disorders and a growing aging population. This presents opportunities for companies like Fougera to expand their product offerings and market reach.

Future Outlook: Fougera's Potential Trajectory

As part of Sandoz, Fougera is well-positioned for future growth and innovation in the generic dermatology market.

Continued Product Development

With Sandoz's resources and Fougera's expertise, we can expect continued development of new generic dermatology products. This could include complex generics and potentially biosimilars in the dermatology space.

Expansion into New Markets

Leveraging Sandoz's global presence, Fougera's products have the potential to reach new international markets. This could lead to significant growth opportunities beyond the US market.

Investment in Research and Development

As part of a larger pharmaceutical company, Fougera may benefit from increased investment in research and development. This could lead to more innovative products and formulations in the dermatology space.

Lessons for the Pharmaceutical Industry

Fougera's success and strategic positioning offer valuable lessons for other players in the pharmaceutical industry.

Importance of Specialization

Fougera's focus on dermatology has allowed it to build deep expertise and a strong market position. This demonstrates the value of specialization in a competitive industry.

Value of Innovation

Even in the generics market, innovation plays a crucial role. Fougera's success with first-to-market generics and packaging innovations highlights the importance of continuous improvement.

Strategic Partnerships and Acquisitions

The acquisition by Sandoz illustrates how strategic partnerships and acquisitions can create value and strengthen market positions in the pharmaceutical industry.

Key Takeaways

  • Fougera Pharmaceuticals has established itself as a leader in generic dermatology products, with a strong focus on topical medications.
  • The acquisition by Sandoz for $1.525 billion positioned the combined entity as the global leader in generic dermatology medicines.
  • Fougera's strengths include specialized expertise in dermatology, a broad product portfolio, and a track record of innovation in product development and packaging.
  • The company's strategic focus on first-to-market generics and customer-centric approach has contributed to its market success.
  • As part of Sandoz, Fougera is well-positioned for future growth, with opportunities for expanded global reach and increased investment in research and development.
  • The pharmaceutical industry can learn from Fougera's success, particularly in the areas of specialization, innovation, and strategic partnerships.

FAQs

  1. What is Fougera Pharmaceuticals' primary focus in the pharmaceutical industry? Fougera Pharmaceuticals primarily focuses on developing and manufacturing generic dermatology products, specializing in topical medications such as creams, ointments, gels, lotions, and solutions.

  2. When was Fougera Pharmaceuticals acquired by Sandoz, and for how much? Sandoz completed the acquisition of Fougera Pharmaceuticals in 2012 for USD 1.525 billion in cash.

  3. How has the acquisition by Sandoz impacted Fougera's market position? The acquisition positioned the combined entity as the #1 global company in generic dermatology medicines, with estimated annual global sales of nearly USD 620 million.

  4. What are some of Fougera's key strengths in the pharmaceutical market? Fougera's key strengths include specialized expertise in dermatology development and manufacturing, a broad product portfolio, innovation in packaging, and a strong track record in obtaining FDA approvals for topical products.

  5. What future opportunities exist for Fougera as part of Sandoz? As part of Sandoz, Fougera has opportunities for continued product development, expansion into new international markets, and increased investment in research and development, potentially leading to more innovative dermatology products.

Sources cited:

  1. https://www.fiercepharma.com/pharma/sandoz-completes-acquisition-of-fougera-pharmaceuticals-positioning-sandoz-as-1-generic
  2. https://www.pharmacytimes.com/view/fougeraprofile-2010
  3. https://www.fiercepharma.com/pharma/sandoz-to-acquire-fougera-pharmaceuticals-becoming-number-one-generic-dermatology-medicines
  4. https://www.pharmacytimes.com/view/fougera-topical-generics-leader-

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.